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The rationale behind active treatment and ablation in asymptomatic WPW is to prevent sudden 
cardiac death (SCD). SCD in asymptomatic WPW syndrome has been noted to vary from 0.15 
to 0.39% over 3-10 years follow up [1,2].                                                                             
SCD happens in WPW in relation to rapid pre-excited atrial fibrillation (AF) with fast 
ventricular response.   It happens in 50% of SCD as the first manifestation. Hence, though the 
incidence of SCD is low in WPW, the same is avoidable in suitably selected cases. It can 
presently be taken care of, by radiofrequency (RF) ablation of the bypass tract without 
significant   morbidity.                                                                            
What then are the criteria to select patients of Asymptomatic WPW who may be predisposed to 
SCD? The markers identified for SCD include: 1. Anterograde effective refractory period of 
accessory pathway (APERP) 240- 250ms; (on isoproternol APERP <200ms?)  2. Shortest Pre-
excited  RR  interval (SPERRI) less than 250ms during or induced AF. 3. Multiple accessory 
pathways   4. Ebsteins anomaly 5. Familial WPW syndrome. The Non invasive parameters of a 
presumed long refractory period of bypass tract (>250ms) include: 1. Intermittent pre-excitation. 
2. Disappearance of pre-excitation during exercise and 3. Disappearance of pre-excitation with 
procainamide.  The predictive value of the non invasive parameters is low and when combined 
with the low risk of RF ablation, most electrophysiologists rely on invasive testing to risk 
stratify asymptomatic patients. In a European survey   44% of EP centers perform invasive 
approach as the first line approach [3] in asymptomatic WPW.                                   
Regardless of how the EP protocol is set, one of the specific parameter taken is anterograde ERP 
<240ms at baseline to decide RF ablation. Additional parameters include Minimum RR interval 
in AF: SPERRI <250ms, and AF induction. Considering all boundary parameters, the best 
binary discriminators are  APERP <240ms at baseline and SPERRI<250ms, which we follow at 
our centre. In perhaps the best prospective follow up study in children age 8-12 yrs, with a 
follow up of 57 months, Pappone et al [4-7]   identified the following 1. Tachyarrhythmia 
inducibility. 2. APERP <240ms 3. Multiple accessory pathways; as independent risk factors for 
life threatening events. Of these APERP and multiple bypass tracts were independent predictors 
by   multivariate   analysis.                                                                                    
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The "PACES /HRS Consensus statement on the management of the Asymptomatic Young 
Patient with a WPW Electrocardiographic pattern" published this week [9] has noted that  
SPERRI  and APERP remain important baseline parameters in risk stratifying asymptomatic 
WPW patients, with high sensitivity and negative predictive value; but with low specificity and 
positive predictive value. They have observed that SPERRI <250ms is superior to APERP 
<240ms in discriminating patients at risk for SCD or VF. The consensus statement has 
recommended that young patients with SPERRI <250ms in AF are at increased risk for SCD 
and RF Catheter ablation is a reasonable option ( Class IIA, Level of evidence B/C ).          
Therefore the most important binary parameters to the invasive Electrophysiologist is SPERRI 
<250ms and APERP < 240ms at baseline (without Isoproternol) to decide RF Ablation.          
The important question raised in this issue by Oliver C et al in this issue of the journal [8] is the 
stability of this parameter of APERP. Does it change temporally at two different occasions? 
Does the APERP assessed by isoproternol also change with time? In short: is the parameter of 
baseline APERP stable and to put it clinically,  can it be accepted as a value to decide RF 
ablation or otherwise in asymptomatic WPW.                                                                   
The changes of baseline APERP temporally in the basal state, as noted by the authors, [8] are 
variable, but not significant enough,   to warrant different approaches or multiple studies to 
decide the need for RF ablation.  A  minor group of patients (15% had a APERP <240ms at the 
second study)  will be left out with an ambiguous decision for medical follow up if the first 
baseline APERP is chosen. But it is also likely that this group will be picked for further 
evaluation and not necessarily  present as SCD.                                                       
The response to APERP on isoproternol has been studied by multiple authors; though 
acceptance of a standard value has not been universally agreed upon.   A value of APERP 
<200ms on isoproternol has been noted as a cut off value, but the dose of the drug has ranged 
from 1-20µg per minute. The authors [8] have noted significant variations in the APERP values 
temporally after isoproternol infusion. A significant group (with APERP >200ms) at first study- 
33% had APERP <200ms at the second study. The conclusion would necessarily imply that the 
ERP values on isoproternol cannot be relied for assessing risk in the asymptomatic WPW. The 
variations are likely to be related to the status of the autonomic system that will modulate the 
electrophysiological properties of the bypass tract and the AV Node.                           
I would like to conclude by noting that APERP estimations are temporally variable. The 
variations are more pronounced during Isoproternol infusion. As a matter of fact all EP 
parameters ranging from Venricular ERP to VT Inducibility are temporally variable; what is 
important is to know the significance of a baseline parameter in relation to the natural history of 
the disease. On the background of the natural history studies by previous authors, the variations 
in the basal state are acceptable and a value of  APERP <240ms  can serve as a binary cut off 
value to indicate and select a potentially high risk group that can undergo RF ablation to reduce 
Sudden Cardiac Death.   EP studies of APERP on isoproternol show significant variations 
temporally and cannot be relied upon as a sole predictor of future risk, independently; however 
it can contribute to the basal study.  Based on the Consensus Statement and Recommendations 
SPERRI <250 ms can serve as a parameter to select patients for catheter ablation [9] and is 
superior to APERP <240ms at baseline. Other risk factors too, as noted above, may be taken 
into consideration in the decision making process. The basal APERP study, inspite of its 
limitations, can   guide the decision to ablate or not in Asymptomatic WPW.                 
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